Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601

Akie, Kenji; Oizumi, Satoshi; Ogura, Shigeaki; Shinagawa, Naofumi; Kikuchi, Eiki; Fukumoto, Shinichi; Harada, Masao; Kinoshita, Ichiro; Kojima, Tetsuya; Harada, Toshiyuki; Fujita, Yuka; Ohsaki, Yoshinobu; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, Masaharu

Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601

Akie, Kenji; Oizumi, Satoshi; Ogura, Shigeaki et al.

Oncology, 2011, 81(2), 84-90

Permalink : https://hdl.handle.net/2115/47435

このアイテムのアクセス数:1,490件（2026-08-13 09:28 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Onc81-2_84-90	pdf	182 KB	1,427

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/47435
タイトル	Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601
著者	Akie, Kenji ; Oizumi, Satoshi ; Ogura, Shigeaki ; Shinagawa, Naofumi ; Kikuchi, Eiki ; Fukumoto, Shinichi ; Harada, Masao ; Kinoshita, Ichiro ; Kojima, Tetsuya ; Harada, Toshiyuki ; Fujita, Yuka ; Ohsaki, Yoshinobu ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi ; Nishimura, Masaharu
著者名 Akie, Kenji
e-Rad_Researcher 10421968 著者名 Oizumi, Satoshi
著者名 Ogura, Shigeaki
著者名 Shinagawa, Naofumi
著者名 Kikuchi, Eiki
著者名 Fukumoto, Shinichi
著者名 Harada, Masao
著者名 Kinoshita, Ichiro
著者名 Kojima, Tetsuya
著者名 Harada, Toshiyuki
著者名 Fujita, Yuka
著者名 Ohsaki, Yoshinobu
著者名 Dosaka-Akita, Hirotoshi
著者名 Isobe, Hiroshi
著者名 Nishimura, Masaharu
言語	英語
キーワード	Irinotecan
	S-1
	Chemotherapy
	Nonplatinum regimens
	Non-small cell lung cancer
	phase II
発行日	2011-10
出版者	Karger
収録物名	Oncology
巻(号)	81(2)
ページ	84-90
抄録	Objective: Platinum-free regimens can represent an alternative for advanced non-small cell lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study evaluated the efficacy and safety of combined irinotecan and S-1 for chemotherapy-naïve advanced NSCLC. Methods: Chemotherapy consisted of 4-week cycles of intravenous irinotecan (100 mg/m2, days 1 and 15) and oral S-1 (80 mg/m2, days 1-14). The primary endpoint was response rate, while secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. Results: A total of 112 cycles was administered to 40 patients (median, 3 cycles; range 1-6 cycles). Twelve patients showed partial response (PR) and 17 patients exhibited stable disease (SD), representing a response rate of 30% and a disease control rate of 72.5%. Median survival time and median PFS were 16.1 months and 4.8 months, respectively. Hematological toxicities of grade 3 or 4 were neutropenia (32.5%) and anemia (5.0%). The most common non-hematological toxicities of grade 3 or 4 included diarrhea (15.0%) and anorexia (17.5%). Patients homo- or heterozygous for UGTA1A*6 tended to show a higher incidence of grade 3 diarrhea (p = 0.055). Conclusion: The combination of irinotecan and S-1 offers good efficacy and tolerability for previously untreated advanced NSCLC.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	© 2011 S. Karger AG, Basel
PISSN	0030-2414
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1159/000331681